Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Endovia Health Sciences, Inc.Bullish
Endovia Health Sciences will hold a special meeting of stockholders on December 7, 2026, to vote on the issuance of 12,683,908 shares related to Series D preferred stock and a $576,271 convertible note, as well as the issuance of up to 20,000,000 shares under an ELOC agreement. Additionally, shareholders will vote on increasing authorized shares to 800,000,000 and granting the board authority to effect a reverse stock split at a ratio between 1:2 and 1:49.…more
Endovia Health Sciences, Inc.
C/M Capital Master Fund, LP, C/M Capital Partners, LP, Thomas Walsh, and Jonathan Juchno have jointly filed a Schedule 13G regarding Endovia Health Sciences, Inc. This filing serves as a joint filing agreement formalizing their collective reporting status.…more
Endovia Health Sciences, Inc.
Endovia Health Sciences has amended its existing securities purchase agreement with C/M Capital Master Fund, LP to immediately increase the beneficial ownership limitation from 4.99% to 9.99%. The parties also agreed to waive notice requirements and other provisions within the original agreement that are inconsistent with this amendment.…more
13 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
Endovia Gains FDA Pathway for Canine Cancer Pain Drug
Endovia's canine bone cancer pain treatment, CannEpil, has qualified for the FDA's minor use pathway, allowing for potential conditional approval. The company is now coordinating with regulators and establishing manufacturing capabilities to target a 2027 product launch.…more
●●●●●●●● ●●●●● ●●●●●●
Endovia Health shares soared in after-hours trading after closing the first tranche of funding from a hedge fund. The proceeds will be used to advance the development and commercialization of its cannabinoid-based drug, CannEpil.…more
●●●●●●●● ●●●●● ●●●●●●
Endovia Health Sciences has closed its initial funding round to accelerate the development and commercialization of CannEpil. The capital will support the company's FDA-regulated veterinary development program and international commercialization initiatives.…more
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.